PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2025-07-22 DOI:10.1038/s41571-025-01062-6

Patrick Neven, Sileny N. Han

引用次数: 0

Abstract

Next-generation, oral selective oestrogen receptor degraders (SERDs) have been shown to improve outcomes in patients with advanced-stage oestrogen receptor (ER)-positive, HER2-negative breast cancer, particularly those with acquired ESR1 mutations. Now, the proteolysis-targeting chimera (PROTAC) SERD vepdegestrant, which induces ER degradation directly rather than indirectly, has also demonstrated efficacy in this setting, raising questions over the optimal choice and sequencing of treatments.

查看原文本刊更多论文

对于携带获得性ESR1突变的晚期ER+HER2 -乳腺癌，PROTAC SERD vedegestrant的疗效优于氟维司汀

新一代口服选择性雌激素受体降解剂（serd）已被证明可以改善晚期雌激素受体（ER）阳性、her2阴性乳腺癌患者的预后，特别是那些获得性ESR1突变的患者。现在，靶向蛋白水解嵌合体（PROTAC） SERD vedegestrant，直接而非间接诱导内质网降解，也在这种情况下显示出疗效，这引发了关于最佳选择和治疗顺序的问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.